ACHN Share Price

Open 4.09 Change Price %
High 4.29 1 Day 0.16 3.89
Low 4.09 1 Week -0.09 -2.06
Close 4.27 1 Month -0.11 -2.51
Volume 1124801 1 Year -4.15 -49.29
52 Week High 9.49
52 Week Low 3.15
ACHN Important Levels
Resistance 2 4.46
Resistance 1 4.38
Pivot 4.22
Support 1 4.16
Support 2 4.08
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
TOPS 0.44 69.23%
More..
NASDAQ USA Top Gainers Stocks
TOPS 0.44 69.23%
SCHS 0.05 66.67%
ELTK 0.95 53.23%
LOCM 0.09 50.00%
SGMS 34.15 27.19%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
MTSL 0.64 20.75%
WBMD 66.10 19.77%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
CYTX 0.48 -56.76%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

ACHN Technical Analysis 4
As on 24th Jul 2017 ACHN Share Price closed @ 4.27 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.99 & Sell for SHORT-TERM with Stoploss of 4.33 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACHN Target for July
1st Target up-side 5.21
2nd Target up-side 5.65
3rd Target up-side 6.08
1st Target down-side 3.97
2nd Target down-side 3.53
3rd Target down-side 3.1
ACHN Other Details
Segment EQ
Market Capital 720848960.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.achillion.com
ACHN Address
ACHN
300 George Street
New Haven, CT 06511
United States
Phone: 203-724-6000
Fax: 203-624-7003
ACHN Latest News
Interactive Technical Analysis Chart Achillion Pharmaceuticals, Inc. ( ACHN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Achillion Pharmaceuticals, Inc.
ACHN Business Profile
Achillion Pharmaceuticals, Inc., incorporated on August 17, 1998, is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.